Evidence-based evaluation of the global cancer-associated thromboembolism risk assessment tools
OBJECTIVE To evaluate the global cancer-associated thromboembolism risk assessment tools based on evidence-based methods,and to provide methodological reference and evidence-based basis for constructing a specific tool in China.METHODS A comprehensive search was conducted on 6 databases,including CNKI,Wanfang data,VIP,CBM,PubMed,and Embase,as well as on the websites of NCCN,ASCO,ESMO and so on with a deadline of June 30,2022.Furthermore,a supplementary search was conducted in January 2023.The essential characteristics and methodological quality of included risk assessment tools were described and analyzed qualitatively,focusing on comparing each assessment tool's key elements,such as evaluation dimensions,tool performance,risk stratification ability.RESULTS Totally 14 risk assessment tools were included in the study,with a sample size of 208-18 956 cases and an average age distribution of 53.1-74.0 years.The applicable population included outpatient cancer patients,lymphoma patients,and multiple myeloma patients,etc.The common predictive factors were body mass index,venous thromboembolism history,and tumor site.All tools had undergone methodological validation,with 9 presented in a weighted scoring format.Only seven tools were used simultaneously for specificity,sensitivity,negative predictive value(NPV),positive predictive value(PPV)and area under the curve(AUC)or C statistical analysis.CONCLUSIONS The risk of bias in constructing existing tools is high,and the heterogeneity of tool validation results is significant.The overall methodological quality must be improved,and its risk stratification ability must also be investigated.There are still certain limitations in clinical practice in China.
cancer-associated thromboembolismrisk assessment toolsevidence-based research
万方数据
维普
